SecBot SecBot
PRESS-RELEASE ·Filed Aug 27, 2026

PHG

Royal Philips
NEUTRAL
Impact 3/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

This is a routine product collaboration announcement with no financial details. Monitor for future commercial adoption metrics or follow-on regulatory clearances for additional Imricor configurations in the U.S. to gauge potential revenue impact.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$26.92
T+0 close · Aug 27, 2026 · via day close
Latest settled
−8.80%
T+20 · $24.55 · next T+60 in 3d
Vs SPY
−8.30%
α at T+20
Latest observation
+16.42%
T+56 · FF3 residual α
  1. T+0 · Aug 27 $26.92entry
  2. T+1 · 3mo ago −0.74%α −0.52% · $26.72
  3. T+5 · 3mo ago −3.23%α −3.50% · $26.05
  4. T+20 · 8w ago −8.80%α −8.30% · $24.55
  5. T+56 · todayOpen
  6. T+60 · in 3d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Philips and Imricor announced the first commercially available Interventional MR (iMR) lab solution combining Philips' 1.5T MRI platform with Imricor's MR-compatible systems and consumables for cardiac interventions. This is a product collaboration announcement, not a financial event, and represents a strategic expansion of Philips' MRI capabilities into interventional procedures. No financial terms or revenue projections were disclosed, making this a routine product development milestone for a large-cap company like Philips.

Key Facts

  • Philips and Imricor announced a new iMR lab solution combining Philips' 1.5T MRI platform with Imricor's portfolio of MR-compatible systems and consumables for cardiac interventions.
  • The solution is commercially available immediately in CE-marked markets and, in some configurations, the U.S.
  • The iMR lab solution is built on Philips' BlueSeal helium-free MRI technology.
  • No financial terms, deal value, or revenue projections were disclosed in the press release.

Financial Impact

No financial terms disclosed; product collaboration with no stated revenue or deal value.

Risk Factors

  • No financial terms disclosed, making it difficult to assess materiality.
  • Regulatory clearances for additional configurations in the U.S. are pending and may face delays.

Market Snapshot

Exchange
OTC
Sector
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Analyst Consensus
55% bullish (29 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3352083

US Market Status

Market Closed · Opens in 7h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 27, 2026